At a news briefing today, neonatal experts urged pediatricians and parents to take action to protect premature babies during the upcoming virus season, which begins in October and lasts through April"”and in some parts of the country, beyond then.
More than 500,000 premature infants are born each year in the United States, approximately one every 60 seconds. Underdeveloped lungs and weak immune systems leave these fragile patients susceptible to respiratory illnesses.
Clinical experts from Children's Hospital Boston and the National Association of Neonatal Nurses lead media teleconference to review data and offer advice on safeguarding preemie health.
Noted endocrinologist, Marc Sandberg, MD, is available to answer questions and talk with reporters about the implications of inhaled insulin in the context of the current state-of-the-art insulin delivery technologies.
Tercica, Inc. announced today that the FDA has approved Increlex(TM) for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
A review article examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin as replacement therapy in patients with primary immunodeficiency disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.
New research shows that a naturally-produced protein, KDI tri-peptide, can block the damaging effects of glutamate, a substance that is released by the body in response to CNS trauma and neurodegenerative disorders.
The 2005 U.S. News & World Report's "America's Best Hospitals" issue has ranked New York City's Hospital for Special Surgery (HSS) No. 2 in orthopedics and No. 3 in rheumatology.
To mark the start of Heart Health Month, The Larry King Cardiac Foundation is hosting a media briefing focused on the "Changing Face of Cardiovascular Disease" and how current research is helping more patients understand the various treatment options available.
Approximately 36 million uninsured Americans will be eligible to receive meaningful savings on a wide range of brand-name and generic prescription products through the Together Rx Access Card program, launched today by 10 companies.
Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD).
Pfizer announced today that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for AROMASIN in the adjuvant treatment of postmenopausal women with estrogen receptor positive or receptor unknown early-stage breast cancer.
Vesicare(r) (solifenacin succinate) has been approved by the FDA for the treatment of overactive bladder with symptoms of urgency, frequency, and urge incontinence. OAB affects an estimated 17-20 million men and women in U.S.
New data showed that AstraZeneca's CRESTOR(R) (rosuvastatin calcium) at 10 and 20 mg reduced LDL-C or "bad" cholesterol by 37 and 46 percent, compared to 32 and 39 percent at similar doses with atorvastatin in African-American patients.
Remarkable advances in assistive technology continue to offer hope for improved function and greater independence, but far too many people are not benefiting from it. The impact on their lives -- and society -- is staggering.
Teleconference to recap presentations given on TB therapies in development from the IUATLD conference in Paris and the ICAAC conference in Washington DC. Latest scientific studies and results will be shared; briefings from the TB Alliance, leading pharmaceutical companies and academic laboratories will participate.
The treatment effect with the investigational drug Macugen extends for two years in patients with neovascular or wet, age-related macular degeneration, who are at risk of losing their vision. A treatment benefit was also seen for patients who received Macugen for two years compared to those only receiving one year of therapy.
Together Rx LLC has appointed Roba Whiteley as its new executive director. Together Rx, the nation's most widely enrolled private prescription savings program, has over 1.4 million cardholders and has saved seniors more than $500 million.
Results of a multi-center, prospective study involving two leading drug-eluting stents were presented today, with data indicating that patients with long areas of vessel blockage treated with the Cypher Sirolimus-eluting Stent had less in-stent late loss and less in-stent restenosis.
The first, integrated data analysis from multiple clinical trials to focus exclusively on the benefits of the Sirolimus-eluting Coronary Stent in women shows that female patients who received the CYPHER® Stent are five times more likely to avoid a repeat reblockage in the treated arteries.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right